We are live on ! Find out more
GNMX

Aevi Genomic Medicine Inc
GNMX

Delisted

GNMX was delisted on the 3rd of February, 2020.

Back to rankings

45 hedge funds and large institutions have $14.6M invested in Aevi Genomic Medicine Inc in 2017 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 12 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

16% more capital invested

Capital invested by funds: $12.6M → $14.6M (+$2M)

8% less funds holding

Funds holding: 49 → 45 (-4)

25% less repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 12

30% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 10

Holders
45
Holders Change
-4
Holders Change %
-8.16%
% of All Funds
1.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
9
Reduced
12
Closed
10
Calls
$12K
Puts
–
Net Calls
+$12K
Net Calls Change
+$13K

Top Buyers

Rank Fund Capital Flow
1
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$4.64M
2
Renaissance Technologies
Renaissance Technologies
New York
+$107K
3
VAM
Verity Asset Management
North Carolina
+$19.8K
4
Wells Fargo
Wells Fargo
California
+$18.4K
5
Citadel Advisors
Citadel Advisors
Florida
+$14.7K

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$671K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$278K
3
2L
22NW LP
Washington
-$195K
4
NCMW
Northern Capital Management (Wisconsin)
Wisconsin
-$192K
5
EMG
ETF Managers Group
New Jersey
-$74K
Name Holding Trade Value Shares
Change 		Change in
Stake
WAP
26
Wealthcare Advisory Partners
Pennsylvania
$6K – – –
CHP
27
Cable Hill Partners
Oregon
$5K +$5.46K +4,000 New
MAM
28
Meeder Asset Management
Ohio
$4K +$775 +568 +20%
JP Morgan Chase
29
JP Morgan Chase
New York
$3K -$25.6K -18,760 -90%
LTFS
30
Ladenburg Thalmann Financial Services
Florida
$2K – – –
LA
31
Legacy Advisors
Pennsylvania
$2K – – –
Royal Bank of Canada
32
Royal Bank of Canada
Ontario, Canada
$2K – – –
CA
33
Calton & Associates
Florida
$2K +$1.67K +1,225 New
Bank of America
34
Bank of America
North Carolina
$1K -$1.24K -911 -48%
AG
35
Advisor Group
Arizona
$1K – – –
IA
36
IFP Advisors
Florida
$1K – – –
IWM
37
IHT Wealth Management
Illinois
$1K – – –
KTC
38
Kistler-Tiffany Companies
Pennsylvania
$1K – – –
TWA
39
TCI Wealth Advisors
Arizona
$1K – – –
BNP Paribas Financial Markets
40
BNP Paribas Financial Markets
France
$2 – – –
2L
41
22NW LP
Washington
– -$195K -155,000 Closed
NCMW
42
Northern Capital Management (Wisconsin)
Wisconsin
– -$192K -152,300 Closed
EMG
43
ETF Managers Group
New Jersey
– -$74K -58,967 Closed
SQA
44
Simon Quick Advisors
New Jersey
– -$50K -39,774 Closed
VF
45
Virtu Financial
New York
– -$45K -35,862 Closed
VanEck Associates
46
VanEck Associates
New York
– -$21K -17,054 Closed
Wolverine Trading
47
Wolverine Trading
Illinois
– -$15.3K -11,233 Closed
Squarepoint
48
Squarepoint
New York
– -$13K -10,500 Closed
PVH
49
Psagot Value Holdings
Israel
– -$5K -4,316 Closed
Simplex Trading
50
Simplex Trading
Illinois
– -$273 -200 -87%
1
2
3

GNMX Hedge Fund Activity: Q4 2017 in Review

45 of the 4,409 institutional investors tracked by Wall St. Rank reported a position in Aevi Genomic Medicine Inc (GNMX) for Q4 2017, worth a combined $14.6M — up 16% from $12.6M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of GNMX and 7 opened new positions — a net loss of 3 holders — while 12 trimmed existing stakes and 9 added.

The largest buyer was Adage Capital Partners, adding an estimated $4.64M. The largest seller was Baker Bros. Advisors, cutting an estimated $671K.

  • 45 institutional investors held Aevi Genomic Medicine Inc (GNMX) as of Q4 2017, down from 49 in Q3 2017.
  • Funds reported $14.6M of Aevi Genomic Medicine Inc stock for Q4 2017, up 16% quarter-over-quarter.
  • 7 funds opened new Aevi Genomic Medicine Inc positions in Q4 2017 and 10 closed out, a net change of -3 holders.
  • The largest Aevi Genomic Medicine Inc buyer in Q4 2017 was Adage Capital Partners, an estimated $4.64M added.
  • The largest Aevi Genomic Medicine Inc seller in Q4 2017 was Baker Bros. Advisors, an estimated $671K sold.

Based on aggregated 13F filings for Q4 2017.